O slideshow foi denunciado.
Utilizamos seu perfil e dados de atividades no LinkedIn para personalizar e exibir anúncios mais relevantes. Altere suas preferências de anúncios quando desejar.

Antibiotic de escalation_in_the_icu___how_is_it.

El concepto de descalamiento de antibióticos, en pacientes en UCI, con sepsis o NAV. Review.

  • Entre para ver os comentários

Antibiotic de escalation_in_the_icu___how_is_it.

  1. 1. Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved. CURRENT OPINION Antibiotic de-escalation in the ICU: how is it best done? Jose Garnacho-Monteroa,b,c , Ana Escoresca-Ortegaa , and Esperanza Ferna´ndez-Delgadoa Purpose of review An antimicrobial policy consisting of the initial use of wide-spectrum antimicrobials followed by a reassessment of treatment when culture results are available is termed de-escalation therapy. Our aim is to examine the safety and feasibility of antibiotic de-escalation in critically ill patients providing practical tips about how to accomplish this strategy in the critical care setting. Recent findings Numerous studies have assessed the rates of de-escalation therapy (range from 10 to 60%) in patients with severe sepsis or ventilator-associated pneumonia as well as the factors associated with de-escalation. De-escalation generally refers to a reduction in the spectrum of administered antibiotics through the discontinuation of antibiotics or switching to an agent with a narrower spectrum. Diverse studies have identified the adequacy of initial therapy as a factor independently associated with de-escalation. Negative impact on different outcome measures has not been reported in the observational studies. Two randomized clinical trials have evaluated this strategy in patients with ventilator-associated pneumonia or severe sepsis. These trials alert us about the possibility that this strategy may be linked to a higher rate of reinfections but without an impact on mortality. Summary Antibiotic de-escalation is a well tolerated management strategy in critically ill patients but unfortunately is not widely adopted. Keywords de-escalation, empirical therapy, hospital-acquired pneumonia, sepsis, survival INTRODUCTION Adequate empiric antimicrobial therapy is crucial in terms of survival in patients with severe infections [1,2]. Moreover, inadequate empirical therapy sig- nificantly increases the length of hospitalization in critically ill patients with severe sepsis or septic shock [3]. With these premises, when microbiolog- ical information is not available yet, the use of broad-spectrum antimicrobial(s) constitutes the backbone of the empirical therapy in critically ill patients. Broad-spectrum antimicrobial treatment is defined as a combination of antibiotics which acts against a wide range of disease-causing bacteria. Certain families of antibiotics (i.e. piperacillin– tazobactam or carbapenems) pose a wide antimicro- bial spectrum and their use as monotherapy is considered as broad-spectrum therapy. It is worth mentioning that carbapenems are the most com- monly used antibiotics in the critical care setting, especially for nosocomial sepsis [4]. However, the use of broad-spectrum antimicro- bial treatment is not without its drawbacks: anti- biotic-related side effects, extra costs and the emergence of bacterial resistance. International guidelines recommend the use of broad-spectrum antibiotics to minimize the risk for inadequate anti- microbial treatment, which has been shown to increase mortality [5–7]. However, once the patho- gen(s) are identified, the empiric antibiotic(s) a Critical Care and Emergency Department, Intensive Care Unit, Virgen del Rocı´o University Hospital, b Instituto de Biomedicina de Sevilla (IBIS), Hospital Universitario Virgen del Rocı´o/CSIC/Universidad de Sevilla and c Spanish Network for Research in Infectious Disease (REIPI), Virgen del Rocı´o University Hospital, Sevilla, Spain Correspondence to Jose Garnacho-Montero, MD, Critical Care and Emergency Department, Intensive Care Unit, Virgen del Rocı´o University Hospital, Avd Manuel Siurot, s/n, 41013, Sevilla, Spain. E-mail: jgarna chom@gmail.com Curr Opin Infect Dis 2015, 28:193–198 DOI:10.1097/QCO.0000000000000141 0951-7375 Copyright ß 2015 Wolters Kluwer Health, Inc. All rights reserved. www.co-infectiousdiseases.com REVIEW
  2. 2. Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved. should be stopped or reduced in number and/or narrowed in spectrum. This strategy termed ‘de- escalation therapy’ appears theoretically correct, capable of promoting therapeutic appropriateness and reducing costs. HOW CAN WE DEFINE DE-ESCALATION THERAPY? Regrettably, a precise consensus definition of de- escalation is still lacking. De-escalation generally refers to a reduction in the spectrum of administered antibiotics through the discontinuation of anti- biotics providing activity against nonpathogenic organisms, discontinuation of antibiotics with similar activity or switching to an agent with nar- rower spectrum. De-escalation is mostly accom- plished by a reduction in the number of antibiotics prescribed [8,9]. Furthermore, the period of time during which the de-escalation should be performed has not been determined. Madaras-Kelly et al. [10 && ] have developed a numerical score to measure the microbial spectrum of antibiotic regimens using a modified Delphi method. This score could be a tool to quantify the rate of de-escalation, although its clinical applica- bility is uncertain. Selective pressure exerted by broad-spectrum antibiotics plays a crucial role in the emergence of multidrug-resistant bacteria. The impact on the microbiota of some antibiotics remains for extended periods of time [11]. The capability of the different antimicrobial agents in altering endogenous flora should be considered for the election of the directed therapy. RATES OF DE-ESCALATION THERAPY IN CRITICALLY ILL PATIENTS Roughly, this strategy is accomplished in approxi- mately 35–50% of the patients with severe sepsis [8,9,12 & ]. The de-escalation rate in ventilator- associated pneumonia (VAP) is very similar, although this strategy is performed only in less than 10% when multidrug-resistant pathogens are implicated [13–15]. However, comparisons among studies are difficult by the absence of standardized definitions of de-escalation, variability of the empirical regimens and the differences in patient populations. Multiple reasons could explain these low rates of antibiotic de-escalation in the critical care set- ting: reluctance to change an antibiotic regimen that has proven to be effective, lack of micro- biological data, poor understanding of how to de-escalate and the controversial data about its effectiveness and safety. CURRENT EVIDENCE ABOUT EFFECTIVENESS AND SAFETY OF DE-ESCALATION THERAPY Observational studies and randomized clinical trials have been conducted to evaluate the clinical impact and safety of de-escalation therapy in patients with severe infections and sepsis. Observational studies De-escalating strategies have been evaluated particularly in VAP, in which the potential risk of multidrug-resistant microorganisms is relatively high. Several studies have shown that de-escalation therapy can be safely provided to patients with ICU- acquired pneumonia and is even associated with lower mortality. Rello et al. [13] found that the mortality rate of VAP patients de-escalated was sig- nificantly lower than in patients with no modifi- cation of the empiric antibiotics (18.4 vs. 43.4%). Similarly, Kollef et al. [16 & ] analysed 398 patients with VAP. The mortality rate was significantly lower among patients in whom therapy was de-escalated (17.0%), than in those experiencing therapy escala- tion (42.6%) and those in whom empirical regimen was not modified (23.7%; P ¼ 0.001) [16 & ]. Giantsou et al. [17], in a prospective observational study of VAP patients, found that antibiotic de-escalation was associated with significantly decreased 28-day mortality (12 vs. 43.5%). In another retrospective study, the de-escalation group had a significantly lower pneumonia-related 30-day mortality rate than in the group with fixed therapy (2.3 vs. 14%) [15]. Of note, a multivariate analysis was not performed in these studies to assess whether this strategy was a protective factor for mortality. De-escalation therapy was also associated with shorter length of stay and with a reduction of resource utilization [17]. Alvarez-Lerma et al. [18], in a prospective multi- centre study of patients with VAP, reported that the KEY POINTS Clinicians should strive to streamline empiric antimicrobial therapy once culture results are available. Current evidence suggests that antibiotic de-escalation is a well tolerated strategy that may be even associated with a better outcome. All initiatives to improve antibiotic prescriptions in critically ill septic patients are completely warranted and should include the streamlining of empirical antibiotics. A precise consensus definition of de-escalation is urgently needed. Respiratory infections 194 www.co-infectiousdiseases.com Volume 28 Number 2 April 2015
  3. 3. Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved. ICU length of stay was significantly longer in culture-positive patients with narrower-spectrum alternatives who were not de-escalated than in cul- ture-positive patients whose therapy was modified accordingly (36.7 vs. 23.7 days). In this study, de- escalation therapy was not a variable independently associated with mortality by logistic regression analysis. This antibiotic policy has also been assessed in patients with severe sepsis. Morel et al. [8] evaluated a heterogeneous group of critically ill patients with severe infections. Their main finding was that de- escalation therapy was associated with a significant reduction of recurrent infection (19 vs. 5%, P ¼ 0.01) without changes in mortality [8]. To evaluate the effect of antibiotic de-escalation on outcomes, we conducted a prospective, observa- tional study involving adults admitted to the ICU with severe sepsis or septic shock. De-escalation of the initial regimen was performed in 219 patients (35%), more commonly in medical than in surgical patients. The hospital mortality rate was 27% in patients with therapy de-escalation, 33% in those with no treatment change and 43% in those with treatment escalation (P ¼ 0.006). Propensity score adjusted multivariate regression analysis identified de-escalation therapy to be as protective for hospital 90-day mortality in the entire cohort, as well as in patients who had received empirical adequate therapy [12 ]. In 754 patients with bacteremic sepsis, Koupe- tori et al. [19] evaluated the impact on the outcome of de-escalation therapy in two periods. Antibiotic streamlining did not impact final outcome, although this strategy led to survival benefit in the second study period [19]. It is worth mentioning a recent observational study performed in 101 neu- tropenic patients with severe sepsis. In this selected population, de-escalation did not negatively affect any prognostic index including early (30-day) or late (1-year) mortality [20]. Randomized clinical trials Two randomized clinical trials have evaluated this antimicrobial strategy with less positive results. Kim et al. [21 ] compared the use of imipenem as well as vancomycin and subsequent de-escalation with maintenance of the above-mentioned anti- microbial regimen in critically ill patients with hospital-acquired pneumonia (HAP). Mortality and length of stay were similar in both arms, but the emergence of multidrug-resistant organisms, especially methicillin-resistant Staphylococcus aur- eus (MRSA), was more frequent in the de-escalation group. In patients with severe sepsis [22 ], a clinical trial concluded that, as compared with the continu- ation of the empirical treatment, de-escalation of antibiotics resulted in prolonged duration of ICU stay (primary outcome measure). A new infection occurred in 16 (27%) patients in the de-escalation group and six (11%) patients in the continuation group (P ¼ 0.03). Again, mortality rate was unaf- fected. HOW CAN DE-ESCALATION BE DONE? De-escalation strategies may differ in different aspects. However, several steps should be always present (Fig. 1). First, before starting antimicrobial therapy, it is indispensable to obtain appropriate cultures in order to identify the pathogens respon- sible for septic conditions. This is the first step to carry out the de-escalation of the empirical therapy because it is challenging to discontinue empirical antibiotics without microbiological documentation of the infection. Second, empirical antibiotic must cover all likely pathogens administering broad-spectrum antimicrobial therapy. Several studies have ident- ified the adequacy of initial antibiotic therapy as an independent factor associated with de-escalation. As expected, the presence of multidrug-resistant bacteria hampered de-escalation [9,13,23]. Third, once the culprit pathogen(s) are identified, the empirical regimen should be adapted to the micro- biological results. De-escalation may also include switching anti- biotics from intravenous to oral route. This change is rarely performed in critically ill patients but is a suitable option in certain situations. De-escalation in infections caused by Gram-positive bacteria Stopping antimicrobials directed against resistant Gram-positive bacteria (i.e. MRSA or Enterococcus faecium) should be the rule when these pathogens are not isolated in clinical samples. Switching to an agent with a narrower spectrum is easily performed for coverage of Gram-positive bacteria susceptible to beta-lactam antibiotics. There is compelling evi- dence that mortality and morbidity of severe infec- tions caused by methicillin-susceptible S. aureus (MSSA) is significantly higher with a glycopeptide than with cloxacillin [24]. Similarly, 30-day mortality of MSSA bacteremia is significantly lower with a beta-lactam with a high activity against MSSA (cloxacillin or cefazoline) than with a third- generation cephalosporin or with piperacillin– tazobactam [25]. Very recently, glycopeptide use Treatment of resistant bacteria Garnacho-Montero et al. 0951-7375 Copyright ß 2015 Wolters Kluwer Health, Inc. All rights reserved. www.co-infectiousdiseases.com 195
  4. 4. Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved. was associated with increased mortality in Entero- coccus faecalis bacteremia [26 ]. De-escalation in infections caused by Gram-negative bacteria Although the use of two active antimicrobials against certain Gram-negative bacilli (i.e. Pseudomo- nas aerugionsa) has been traditionally advocated [27], recent studies clearly demonstrated that the use of combination therapy in the directed therapy does not reduce recurrence rates and is not associ- ated with any survival benefits [28,29]. Similarly, in severe infections caused by Acinetobacter baumannii, the use of monotherapy appears feasible without any obvious negative clinical impact [30]. Therefore, if two active antimicrobials have been initiated to cover Gram-negative bacilli (GNB), switch to mono- therapy can be safely performed once susceptibility results are available. Infections caused by carbape- nemase-producing Klebsiella pneumoniae constitute an exception to this recommendation of monother- apy in the directed therapy [31]. More troublesome is usually the spectrum reduction of the empirically administered antibiotics for Gram-negative bacilli. Whenever possible, carba- penems must be stopped and switched to another antimicrobial with a narrower spectrum and less impact on resistance development [32]. Carbape- nems should be reserved because they frequently constitute the only therapeutic option against GNB such as extended-spectrum beta-lactamase (ESBL)- producing Enterobacteriaceae, Pseudomonas aerugi- nosa or A. baumannii. The likely alternatives are summarized in Table 1. Piperacillin–tazobactam is an option frequently used in the directed therapy when meropenem was used empirically [33]. Recent studies have reported that the susceptibility of P. aeruginosa to imipenem improved after the intro- duction of ertapenem into hospital formularies [34]. De-escalation of antifungal therapy Therapy with an antifungal agent should be dis- continued if fungi (i.e. Candida spp.) are not present in clinical samples. Regarding the switch to an antifungal agent with narrower spectrum, echinocandins are considered the agents of choice for empirical treatment of critically ill patients with invasive candidiasis. In patients with candi- demia, therapy until 14 days after the first negative blood culture is recommended. Recent guidelines include the recommendation to step-down to oral fluconazole after 10 days of intravenous treat- ment if the patient is clinically stable and blood cultures have become negative [35]. The appropri- ate timing of antifungal step-down remains unclear, but this change might be done early and the use of intravenous fluconazole is a valid alternative provided that the strain is susceptible to the azole. Empirical therapy • Early therapy • • Broad spectrum agents Consider combination therapy • Optimization of dose schedule Streamlining of empirical therapy • Stopping of antibiotics • Agents with narrower spectrum • Low impact on microbiota • Optimization of dose schedule • Use oral route if possible • Consider cost Appropriate cultures • Blood • Site of infection De-escalation therapy FIGURE 1. Components of the de-escalation therapy strategy. Respiratory infections 196 www.co-infectiousdiseases.com Volume 28 Number 2 April 2015
  5. 5. Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved. De-escalation therapy in culture-negative infections Regarding de-escalation therapy, particularly chal- lenging are the infections with negative cultures. In a retrospective study, antibiotic therapy was de- escalated in 75% of the patients with culture- negative HAP [36]. Conversely, de-escalation was not performed in patients without a known pathogen in a series of critically ill patients with VAP [13]. It is reasonable to cease empirical vanco- mycin in patients with culture-negative pneumonia and with no MRSA colonization [37]. In other patients without microbiological documentation, streamlining of the empirical therapy should be left to clinical judgement as long as the patient has a good clinical course. CONCLUSION Antibiotic de-escalation is a well tolerated and highly recommended approach in critically ill patients with severe sepsis. The available data suggest that outcomes can be improved with its use. These outcomes include less antibiotic use, shorter duration of therapy and reduced mortality. Nevertheless, we also need more information about which patients can have therapy stopped altogether if cultures are negative and about the timing to carry out the streamlining of the empirical therapy. Acknowledgements None. Financial support and sponsorship No financial support was received for this study. Conflicts of interest There are no conflicts of interest. REFERENCES AND RECOMMENDED READING Papers of particular interest, published within the annual period of review, have been highlighted as: of special interest of outstanding interest 1. Garnacho-Montero J, Garcia-Garmendia JL, Barrero-Almodovar A, et al. Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit Care Med 2003; 31:2742–2751. 2. Valle´s J, Rello J, Ochagavı´a A, et al. Community-acquired bloodstream infection in critically ill adult patients: impact of shock and inappropriate antibiotic therapy on survival. Chest 2003; 123:1615–1624. 3. Garnacho-Montero J, Ortiz-Leyba C, Herrera-Melero I, et al. Mortality and morbidity attributable to inadequate empirical antimicrobial therapy in patients admitted to the ICU with sepsis: a matched cohort study. J Antimicrob Chemother 2008; 61:436–441. 4. Dı´az-Martı´n A, Martı´nez-Gonza´lez ML, Ferrer R, et al., Edusepsis Study Group. Antibiotic prescription patterns in the empiric therapy of severe sepsis: combination of antimicrobials with different mechanisms of action reduces mortality. Crit Care 2012; 16:R223. Table 1. Different options for de-escalation of beta-lactams commonly used in the empirical therapy to cover Gram-negative bacteria Empirical therapy De-escalation Commentary Imipenem or meropenem Ertapenem Ertapenem use may improve susceptibility of Pseudomonas spp. to imipenem/meropenem Piperacillin and tazobactam Broad-spectrum agent including anaerobic coverage Ceftazidime or cefepime No anaerobic coverage Ciprofloxacin or levofloxacin Their widespread use has been linked with a rising prevalence of MDR pathogens, including gram-negatives, MRSA and VRE. Ceftriaxone or cefotaxime No anaerobic coverage Cloxacillin If MSSA is the culprit pathogen Piperacillin and tazobactam Ceftazidime or cefepime No anaerobic coverage Ciprofloxacin or levofloxacin Their widespread use has been linked with a rising prevalence of MDR pathogens, including Gram-negatives, MRSA and VRE. Ceftriaxone or cefotaxime Cloxacillin Lower mortality rate of MSSA bacteremia treated with cloxacillin Ceftazidime or cefepime Ceftriaxone or cefotaxime No anaerobic coverage Amoxicillin-Clavulanate Anaerobic coverage Cloxacillin Only if MSSA is the culprit pathogen Ceftriaxone or cefotaxime Amoxicillin-clavulanate Anaerobic coverage Cloxacillin Only if MSSA is the culprit pathogen MDR, multidrug-resistant; MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-susceptible Staphylococcus aureus; VRE, vancomycin-resistant Enterococcus. Treatment of resistant bacteria Garnacho-Montero et al. 0951-7375 Copyright ß 2015 Wolters Kluwer Health, Inc. All rights reserved. www.co-infectiousdiseases.com 197
  6. 6. Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved. 5. American Thoracic Society/Infectious Diseases Society of America. Guide- lines for the management of adults with hospital-acquired, ventilator-asso- ciated, and healthcare associated pneumonia. Am J Respir Crit Care Med 2005; 171:388–416. 6. Dellinger RP, Levy MM, Rhodes A, et al. Surviving Sepsis Campaign: Inter- national Guidelines for Management of Severe Sepsis and Septic Shock: 2012. Crit Care Med 2013; 41:580–637. 7. Averbuch D, Orasch C, Cordonnier C, et al., ECIL4, a joint venture of EBMT, EORTC, ICHS, ESGICH/ESCMID and ELN. European guidelines for empiri- cal antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia. Haematologica 2013; 98:1826–1835. 8. Morel J, Casoetto J, Jospe´ R, et al. De-escalation as part of a global strategy of empiric antibiotherapy management. A retrospective study in a medico- surgical intensive care unit. Crit Care 2010; 14:R225. 9. Heenen S, Jacobs F, Vincent J-L. Antibiotic strategies in severe nosocomial sepsis: why do we not deescalate more often? Crit Care Med 2012; 40:1404–1409. 10. Madaras-Kelly K, Jones M, Remington R, et al. Development of an antibiotic spectrum score based on Veterans Affairs culture and susceptibility data for the purpose of measuring antibiotic de-escalation: a modified Delphi approach. Infect Control Hosp Epidemiol 2014; 35:1103–1113. An interesting initiative to develop a numerical score to measure the microbial spectrum of antibiotic regimens. 11. Jernberg C, Lo¨fmark S, Edlund C, Jansson JK. Long-term impacts of antibiotic exposure on the human intestinal microbiota. Microbiology 2010; 156:3216– 3223. 12. Garnacho-Montero J, Gutie´rrez-Pizarraya A, Escoresca-Ortega A, et al. De- escalation of empirical therapy is associated with lower mortality in patients with severe sepsis and septic shock. Intensive Care Med 2014; 40:32–40. A prospective, observational study demonstrating that de-escalation of antibiotic therapy in patients with sepsis was associated with significantly decreased hospital and 90-day mortality. 13. Rello J, Vidaur L, Sandiumenge A, et al. De-escalation therapy in ventilator- associated pneumonia. Crit Care Med 2004; 32:2183–2190. 14. Eachempati SR, Hydo LJ, Shou J, Barie PS. Does de-escalation of antibiotic therapy for ventilator-associated pneumonia affect the likelihood of recurrent pneumonia or mortality in critically ill surgical patients? J Trauma 2009; 66:1343–1348. 15. Joung MK, Lee JA, Moon SY, et al. Impact of de-escalation therapy on clinical outcomes for intensive care unit-acquired pneumonia. Crit Care 2011; 15:R79. 16. Kollef MH, Morrow LE, Niederman MS, et al. Clinical characteristics and treatment patterns among patients with ventilator-associated pneumonia. Chest 2006; 129:1210–1218. A multicentre experience with VAP therapy documenting the frequency and con- sequences of a de-escalation strategy. The use of a de-escalation approach led to reduced mortality compared with an escalating therapy strategy or with no change. 17. Giantsou E, Liratzopoulos N, Efraimidou E, et al. De-escalation therapy rates are significantly higher by bronchoalveolar lavage than by tracheal aspirate. Intensive Care Med 2007; 33:1533–1540. 18. Alvarez-Lerma F, Alvarez B, Luque P, et al., ADANN Study Group. Empiric broad-spectrum antibiotic therapy of nosocomial pneumonia in the intensive care unit: a prospective observational study. Crit Care 2006; 10:R78. 19. Koupetori M, Retsas T, Antonakos N, et al., Hellenic Sepsis Study Group. BloodstreaminfectionsandsepsisinGreece:over-timechangeofepidemiology and impact of de-escalation on final outcome. BMC Infect Dis 2014; 14:272. 20. Mokart D, Slehofer G, Lambert J, et al. De-escalation of antimicrobial treat- ment in neutropenic patients with severe sepsis: results from an observational study. Intensive Care Med 2014; 40:41–49. 21. Kim JW, Chung J, Choi SH, et al. Early use of imipenem/cilastatin and vancomycin followed by de-escalation versus conventional antimicrobials without de-escalation for patients with hospital-acquired pneumonia in a medical ICU: a randomized clinical trial. Crit Care 2012; 16:R28. A unicentre, open-label randomized trial of patients with HAP who were assigned to de-escalation or continuation of empirical regimen. Although mortality was similar in both groups, emergence of multidrug resistance was significantly higher in the de-escalation group. 22. Leone M, Bechis C, Baumstarck K, et al., AZUREA Network Investigators. De- escalation versus continuation of empirical antimicrobial treatment in severe sepsis: a multicenter non-blinded randomized noninferiority trial. Intensive Care Med 2014; 40:1399–1408. A multicentre, non-blinded, randomized, noninferiority trial of patients with severe sepsis who were assigned to de-escalation or continuation of empirical antimi- crobial treatment. Although mortality was similar in both groups, length of ICU stay was significantly longer in the de-escalation group. 23. Gonzalez L, Cravoisy A, Barraud D, et al. Factors influencing the implementa- tion of antibiotic de-escalation and impact of this strategy in critically ill patients. Crit Care 2013; 17:R140. 24. Gonza´lez C, Rubio M, Romero-Vivas J, et al. Bacteremic pneumonia due to Staphylococcus aureus: a comparison of disease caused by methicillin- resistant and methicillin-susceptible organisms. Clin Infect Dis 1999; 29:1171–1177. 25. Paul M, Zemer-Wassercug N, Talker O, et al. Are all beta-lactams similarly effective in the treatment of methicillin-sensitive Staphylococcus aureus bacteraemia? Clin Microbiol Infect 2011; 17:1581–1586. 26. Foo H, Chater M, Maley M, van Hal SJ. Glycopeptide use is associated with increased mortality in Enterococcus faecalis bacteraemia. J Antimicrob Che- mother 2014; 69:2252–2257. A recent study demonstrating that compared with the use of a beta-lactam, glycopeptide treatment was an independent predictor of 30-day mortality in patients with E. faecalis bacteremia. 27. Safdar N, Handelsman J, Maki DG. Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis. Lancet Infect Dis 2004; 4:519–527. 28. Garnacho-Montero J, Sa-Borges M, Sole-Violan J, et al. Optimal management therapy for Pseudomonas aeruginosa ventilator-associated pneumonia: an observational, multicenter study comparing monotherapy with combination antibiotic therapy. Crit Care Med 2007; 35:1888–1895. 29. Pen˜a C, Suarez C, Ocampo-Sosa A, et al., Spanish Network for Research in Infectious Diseases (REIPI). Effect of adequate single-drug vs combination antimicrobial therapy on mortality in Pseudomonas aeruginosa bloodstream infections: a post hoc analysis of a prospective cohort. Clin Infect Dis 2013; 57:208–216. 30. Lo´ pez-Corte´s LE, Cisneros JM, Ferna´ndez-Cuenca F, et al., GEIH/REIPI- Ab2010 Group. Monotherapy versus combination therapy for sepsis due to multidrug-resistant Acinetobacter baumannii: analysis of a multi- centre prospective cohort. J Antimicrob Chemother 2014; 69:3119– 3126. 31. Tumbarello M, Viale P, Viscoli C, et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis 2012; 55:943–950. 32. Kuo HY, Chang KC, Kuo JW, et al. Imipenem: a potent inducer of multidrug resistance in Acinetobacter baumannii. Int J Antimicrob Agents 2012; 39:33– 38. 33. De Waele JJ, Ravyts M, Depuydt P, et al. De-escalation after empirical meropenem treatment in the intensive care unit: fiction or reality? J Crit Care 2010; 25:641–646. 34. Goldstein EJ, Citron DM, Peraino V, et al. Introduction of ertapenem into a hospital formulary: effect on antimicrobial usage and improved in vitro sus- ceptibility of Pseudomonas aeruginosa. Antimicrob Agents Chemother 2009; 53:5122. 35. Cornely OA, Bassetti M, Calandra T, et al., ESCMID Fungal Infection Study Group. ESCMIDÃ guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect 2012; 18 (Suppl 7):19–37. 36. Schlueter M, James C, Dominguez A, et al. Practice patterns for antibiotic de- escalation in culture-negative healthcare-associated pneumonia. Infection 2010; 38:357–362. 37. Boyce JM, Pop OF, Abreu-Lanfranco O, et al. A trial of discontinuation of empiric vancomycin therapy in patients with suspected methicillin-resistant Staphylococcus aureus health care-associated pneumonia. Antimicrob Agents Chemother 2013; 57:1163–1168. Respiratory infections 198 www.co-infectiousdiseases.com Volume 28 Number 2 April 2015